Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial

被引:0
作者
Yong-an Ye
Xiao-ke Li
Da-qiao Zhou
Xiao-ling Chi
Qin Li
Li Wang
Bing-jiu Lu
De-wen Mao
Qi-kai Wu
Xian-bo Wang
Ming-xiang Zhang
Jing-dong Xue
Yong Li
Wei Lu
Jian-chun Guo
Feng Jiang
Xin-wei Zhang
Hong-bo Du
Xian-zhao Yang
Hui Guo
Da-nan Gan
Zhi-guo Li
机构
[1] Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine,Institute of Liver Diseases, Beijing University of Chinese Medicine
[2] Shenzhen Traditional Chinese Medicine Hospital,Department of Hepatology
[3] Guangdong Hospital of Traditional Chinese Medicine,Department of Hepatology
[4] Mengchao Hepatobiliary Hospital of Fujian Medical University,Department of Hepatology
[5] Public Health Clinical Center of Chengdu,Department of Hepatology
[6] Liaoning Hospital of Traditional Chinese Medicine,Department of Hepatology
[7] the First Affiliated Hospital of Guangxi University of Chinese Medicine,Department of Hepatology
[8] the Third People’s Hospital of Shenzhen,Department of Hepatology
[9] Beijing Ditan Hospital,Department of Hepatology
[10] the Sixth People’s Hospital of Shenyang,Department of Hepatology
[11] Shaanxi Hospital of Traditional Chinese Medicine,Department of Hepatology
[12] Shandong Hospital of Traditional Chinese Medicine,Department of Hepatology
[13] the Second People’s Hospital of Tianjin,Department of Hepatology
[14] Xixi Hospital of Hangzhou,Department of Hepatology
[15] 302 Military Hospital of China,Department of Hepatology
[16] the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Department of Hepatology
来源
Chinese Journal of Integrative Medicine | 2018年 / 24卷
关键词
chronic hepatitis B; Chinese herbal medicine; Tiaogan-Jianpi-Jiedu Granule; Tiaogan- Yipi Granule; protocol; randomized-controlled trial;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:653 / 660
页数:7
相关论文
共 224 条
[1]  
Ott JJ(2012)Global epidemiology of hepatitis B virus infection: new estimates of age–specific HBsAg seroprevalence and endemicity Vaccine 30 2212-2219
[2]  
Stevens GA(2004)Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 97-107
[3]  
Groeger J(2009)Management of hepatitis B in China Chin Med J 122 3-4
[4]  
Wiersma ST(2012)Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 6 531-561
[5]  
Lavanchy D(2015)Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma World J Hepatol 7 1742-1010
[6]  
Lu FM(2013)Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency Clin Gastroenterol Hepatol 11 1004-1332
[7]  
Zhuang H(2014)HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability Gut 63 1325-1887
[8]  
Liaw Y(2013)Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: Is the glass half full or half empty Hepatology 58 1885-130
[9]  
Kao J(2011)The clinical implications of hepatitis B virus genotype: recent advances J Gastroenterol Hepatol 26 123-1002
[10]  
Piratvisuth T(2000)Hepatitis B genotypes and the response to interferon therapy J Hepatol 33 998-1430